Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 4, MULTICENTER, OPEN-LABEL SAFETY STUDY OF CRISABOROLE OINTMENT 2% IN CHILDREN AGED 3 MONTHS TO LESS THAN 24 MONTHS WITH MILD TO MODERATE ATOPIC DERMATITIS

NCT03356977 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT03356977
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03356977 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 4, MULTICENTER, OPEN-LABEL SAFETY STUDY OF CRISABOROLE OINTMENT 2% IN CHILDREN AGED 3 MONTHS TO LESS THAN 24 MONTHS WITH MILD TO MODERATE ATOPIC DERMATITIS
Lead sponsor
Pfizer
Phase
Phase 4
Overall status
Completed
Start date
January 16, 2018
Completion date
April 12, 2019
Enrollment
137 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis